Patents Issued in May 9, 2023
  • Patent number: 11642379
    Abstract: The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: May 9, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
    Inventors: Rajni Agarwal, Janel Long Boyle, Morton J. Cowan, Christopher Dvorak, Hye Sook Kwon, Anne Le, Aaron Logan, Wendy Pang, Robertson Parkman, Maria-Grazia Roncarolo, Kenneth Weinberg, Judith A. Shizuru, Susan Sweeney Prohaska, Agnieszka Czechowicz, Irving L. Weissman
  • Patent number: 11642380
    Abstract: Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: May 9, 2023
    Assignee: WELL STONE CO.
    Inventors: Yoichi Ishii, Takeshi Okamoto, Sayaka Makino
  • Patent number: 11642381
    Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: May 9, 2023
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Beth Anne-Szkudlarek Brown, Joshua Erickson, Messac Che Neba
  • Patent number: 11642382
    Abstract: A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: May 9, 2023
    Assignee: Seed Health, Inc.
    Inventor: Joseph E. Kovarik
  • Patent number: 11642383
    Abstract: This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: May 9, 2023
    Inventor: Arman Zhenisovich Lurye
  • Patent number: 11642384
    Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a SPINK5 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Netherton Syndrome); and articles of manufacture or kits thereof.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: May 9, 2023
    Assignee: Krystal Biotech, Inc.
    Inventors: Pooja Agarwal, Suma Krishnan, John C. Freedman
  • Patent number: 11642385
    Abstract: This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: May 9, 2023
    Assignee: PSILO SCIENTIFIC LTD.
    Inventors: Benjamin Lightburn, Ryan Moss, Lisa Ranken
  • Patent number: 11642386
    Abstract: The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of Actinidia chinensis. Also encompassed are methods of preparing these compositions. Further encompassed are methods of using these compositions, in particular, for treating or preventing disorders of the gastrointestinal system, including amongst others: inflammation, constipation, bowel irregularity, microbiota imbalances, irritable bowel syndrome, and inflammatory bowel disease.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: May 9, 2023
    Assignee: ANAGENIX IP LIMITED
    Inventors: Juliet Ansell, Paul Blatchford
  • Patent number: 11642387
    Abstract: Disclosed is a composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides as active ingredients, and the ginseng berry polysaccharides exhibit an inhibitory effect on influenza virus activity or infection due to specific ingredients and structures and, specifically, have an excellent inhibitory effect on neuraminidase activity.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 9, 2023
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Donghyun Cho, Suhwan Kim, Juewon Kim, Chan Woong Park, Dae Bang Seo
  • Patent number: 11642388
    Abstract: An antidepressant compound preparation and a preparation method for same were disclosed, The antidepressant includes the following raw materials of Hypericum perforatum L., Paeonia lactiflora Pall., Gardenia jasminoides Ellis, Albizia julibrissin Durazz. and Moutan cortex. The raw materials are weighed in proportion to obtain extracts respectively, and the extracts are mixed to prepare a compound preparation. The compound preparation prepared by the present invention has the advantages of simple preparation, safety, low toxic and side effects, no dependence, etc., and can effectively alleviate depression mood.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: May 9, 2023
    Assignees: CHENLAND NUTRITION ALS INC., QINGDAO CHENLAND PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Shengcan Zou, Jiancheng Zong, Wenyu Li, Lei Zong, Zengliang Zhang, Shanglong Wang
  • Patent number: 11642389
    Abstract: The invention is directed to a composition comprising a green tea flower extract and methods for making and using the composition in the management of a healthy body weight. The composition can comprise an aqueous alcohol extract of Camellia sinensis that is administered to a patient to provide a method for maintaining a healthy body weight.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: May 9, 2023
    Assignee: Vidya Herbs, Inc.
    Inventor: Kodimule Shyam Prasad
  • Patent number: 11642390
    Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: May 9, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Panayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
  • Patent number: 11642391
    Abstract: Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 9, 2023
    Assignee: Vascular Biosciences
    Inventors: David Mann, Erkki Ruoslahti, Masanobu Komatsu
  • Patent number: 11642392
    Abstract: Provided is a novel use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and thus having an amino acid sequence similar to that of galanin, with a therapeutic agent of uremia, and the therapeutic agents of uremia according to the presently claimed subject matter include alarin as the main ingredient.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: May 9, 2023
    Assignee: JU TIDE CO., LTD.
    Inventor: Jong-Chul Kim
  • Patent number: 11642393
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 9, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11642394
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: May 9, 2023
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
  • Patent number: 11642395
    Abstract: Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: May 9, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Edgar Davidson Charles, III, Rose C. Christian, Yi Luo
  • Patent number: 11642396
    Abstract: This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal ?-interferon.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: May 9, 2023
    Assignee: AIM ImmunoTech Inc.
    Inventors: William A. Carter, David R. Strayer
  • Patent number: 11642397
    Abstract: The present invention relates to a method and a drug for preventing or treating osteoarthritis by plasminogen. Specifically, the present invention involves administering an effective amount of plasminogen to an osteoarthritis subject for treating the osteoarthritis. In addition, the present invention further relates to an osteoarthritis treatment drug comprising plasminogen, a product, and a kit.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: May 9, 2023
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Patent number: 11642398
    Abstract: The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: May 9, 2023
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventor: Mark Brader
  • Patent number: 11642399
    Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: May 9, 2023
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: Shilpa Palan, Sai Man Liu, Gavin Stephen Hackett
  • Patent number: 11642400
    Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: May 9, 2023
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Peiwen Yu, Kuo-Pao Lai, Wei-Han Lee, I-Ju Chen, Shu-Yi Lin, Yih-Huang Hsieh
  • Patent number: 11642401
    Abstract: Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: May 9, 2023
    Assignee: Regents of the University of Minnesota
    Inventors: David B. Masopust, Jr., Vaiva D. Vezys
  • Patent number: 11642402
    Abstract: A method of producing an immunotherapy vaccine is provided. The method includes performing a heat treatment to exosomes separated from cancer cells or body fluids including blood of a cancer patient to promote inactivation of proteolytic enzymes in the exosomes, and introducing or co-culturing the exosomes in dendritic cells derived from blood of the cancer patient or a healthy person to make antigen-presenting cells.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: May 9, 2023
    Assignees: CYTIX INC., KINKO CAPITAL CO.. LTD.
    Inventors: Sadatoshi Sakuma, Michiyo Osono, Eriko Oka
  • Patent number: 11642404
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Grant
    Filed: January 18, 2021
    Date of Patent: May 9, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Salah Mecheri, Robert Menard, Claudia Demarta-Gatsi
  • Patent number: 11642405
    Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 9, 2023
    Assignees: Washington University, BLUEWILLOW BIOLOGICS
    Inventors: Shabaana Abdul Khader, Mushtaq Ahmed, Ali Fattom, Douglas Smith, Tarek Hamouda
  • Patent number: 11642406
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: May 9, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
  • Patent number: 11642407
    Abstract: Provided herein are universal prophylactic compositions for preventing infection with influenza viruses by directing the immune response to highly conserved regions of the virus. Also provided are universal therapeutic compositions for treating influenza infection by targeting the highly conserved regions. Methods for using the prophylactic and therapeutic compositions are also provided.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 9, 2023
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Darrell O. Ricke
  • Patent number: 11642408
    Abstract: An antigen variant and a use thereof are disclosed. The antigen variant is a protein, among surface proteins (gE) of the varicella zoster virus, exhibits a high expression level and high immunogenicity, and thus, when the antigen variant is used as a vaccine composition, the vaccine composition has more excellent safety compared to a live virus vaccine, and the antigen variant exhibits a higher expression level in a host cell compared to other antigens. The antigen variant is useful as a vaccine for preventing or treating chicken pox or herpes zoster caused by the varicella zoster virus.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: May 9, 2023
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Hyo Jung Nam, Ga Young Ji, Eunmi Kim
  • Patent number: 11642409
    Abstract: The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 9, 2023
    Assignee: Massachusetts Insttute of Technology
    Inventors: Darrell J. Irvine, Karl Dane Wittrup, Tyson Moyer, Yash Agarwal
  • Patent number: 11642410
    Abstract: This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 9, 2023
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Robert H. Grubbs, Marshall L. Stoller, Hoyong Chung, Alissa M. Fitzgerald, Thomas W. Kenny, Renee M. Thomas
  • Patent number: 11642411
    Abstract: The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 9, 2023
    Assignee: BIOFRONTERA BIOSCIENCE GMBH
    Inventor: Hermann Lübbert
  • Patent number: 11642412
    Abstract: The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: May 9, 2023
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Robert L. Cleek, Edward H. Cully, Paul D. Drumheller, Theresa A. Holland
  • Patent number: 11642413
    Abstract: Disclosed herein are novel compounds for degrading Tau protein aggregates, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof. Also disclosed herein are uses of the compounds, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof in manufacture a medicament for treating a tauopathy, as well as method for aiding in the treatment of a tauopathy or treating a tauopathy in a subject.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: May 9, 2023
    Assignee: APRINOIA THERAPEUTICS LIMITED
    Inventors: Paul Tempest, Ming-Kuei Jang, Yih-Shyan Lin
  • Patent number: 11642414
    Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: May 9, 2023
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
  • Patent number: 11642415
    Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: May 9, 2023
    Assignee: Ascendis Pharma A/S
    Inventors: Sebastian Stark, Thomas Knappe, Harald Rau, Nicola Bisek, Burkhardt Laufer, Samuel Weisbrod, Tobias Voigt
  • Patent number: 11642416
    Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
  • Patent number: 11642417
    Abstract: Provided herein are protein complexes comprising a sensor domain and a therapeutic domain linked by a linker, and methods of use thereof. In aspects of the present disclosure, activity of the therapeutic domain comprises a dependence on sensor domain binding to target markers.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: May 9, 2023
    Assignee: Bonum Therapeutics, Inc.
    Inventors: John Thomas Mulligan, Shannon Lee Okada, Justin Richard Killebrew, Diane Louise Hollenbaugh
  • Patent number: 11642418
    Abstract: Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti-PD-L1 nanobody and a radionuclide, and can be used for non-invasive detecting of expression of the object PD-L1 to be detected. The immunoconjugate of the invention has small size and high specificity, and is suitable for systemic detection which simultaneously targets primary and metastatic tumors, and has high accuracy and low radiation dose.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: May 9, 2023
    Assignee: NANOMAB TECHNOLOGY LIMITED
    Inventors: Hong Hoi Ting, Chung Lim Wong
  • Patent number: 11642419
    Abstract: The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 9, 2023
    Assignee: The Regents of the University of Michigan
    Inventors: Anna A. Schwendeman, Yuqing Eugene Chen, Yanhong Guo, Jifeng Zhang, Wenmin Yuan, Emily Morin
  • Patent number: 11642420
    Abstract: A method of preparing a nanoparticle pharmaceutical delivery system. A nanoparticle pharmaceutical delivery system. A method of preparing a targeted nanoparticle pharmaceutical delivery system. A targeted nanoparticle pharmaceutical delivery system.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: May 9, 2023
    Assignee: ADEIRA PHARMA, LLC
    Inventors: Kendall Killgore, John Hefti
  • Patent number: 11642421
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: May 9, 2023
    Assignee: TranscripTx, Inc.
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Patent number: 11642422
    Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 9, 2023
    Assignees: Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P., Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Consorcio Centro de Investigación Biomédica en Red, M.P.
    Inventors: Jose Carlos Segovia, Maria G. Gomez, Susana Navarro, Nestor Meza, Juan Antonio Bueren, Maria G. Bravo
  • Patent number: 11642423
    Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 9, 2023
    Assignee: Salk Institute for Biological Studies
    Inventor: Neal Dilip Amin
  • Patent number: 11642424
    Abstract: The present invention relates to a clothes-handing apparatus comprising: a cabinet having a holder opening provided at an upper panel; an air moving part provided inside the cabinet so as to generate an air flow; a holder which is withdrawable from the cabinet through the holder opening and on which clothes are hung; and holder air holes provided at the holder so as to supply air to the clothes hung on the holder.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: May 9, 2023
    Assignee: LG Electronics Inc.
    Inventors: Miju Shin, Seonglak Kim
  • Patent number: 11642425
    Abstract: Provided are a method and an apparatus for inactivating bacteria or viruses attached to an object while suppressing generation of a strange odor. The method for inactivating bacteria or viruses includes a step (a) of irradiating with ultraviolet light having an optical output at a specific wavelength in a range of 200 nm to 235 nm. The step (a) is a step of irradiating with the ultraviolet light is performed so that an irradiance (X) [mW/cm2] (X>0) and an integrated irradiation dose within two hours (Y) [mJ/cm2] satisfy the following formula (1) 0<Y<10.704X?0.373??(1).
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: May 9, 2023
    Assignee: Ushio Denki Kabushiki Kaisha
    Inventor: Yoshihiko Okumura
  • Patent number: 11642426
    Abstract: A UV sanitizing device including a sanitizing interface having a top surface arranged to support a device positioned above the sanitizing interface where the sanitizing interface includes a translucent material arranged to allow UV light to pass through An adjustable UV emission interface, positioned adjacent to the sanitizing interface, arranged to adjustably conform to the shape of a device facing the sanitizing interface, and arranged to emit the UV light toward the sanitizing interface in the shape of the device. The adjustable UV emission interface includes UV emission interface cells such that, when a first portion of the UV emission interface cells is activated and a second portion of the UV emission interface cells is deactivated, the UV emission interface conforms to the shape of the device. Each cell of UV emission interface cells includes a sensor arranged to detect a portion of the device facing the sanitizing interface.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 9, 2023
    Assignee: Nittany Solutions Group, LLC
    Inventors: Robert F. McKeon, Scott A. Treser
  • Patent number: 11642427
    Abstract: A system for disinfecting an enclosed area may include a humidity sensor, and a fogging device including a portable housing, an atomizing disinfectant generator carried by the portable housing, at least one output circuit carried by the portable housing, and a processor carried by the portable housing. The processor may be configured to determine a humidity level within the enclosed area based upon the humidity sensor, operate a humidity control device via the at least one output circuit responsive to the determined humidity control level being outside of a starting humidity range, cease operating the humidity control device responsive to the humidity level being within the starting humidity range based upon the humidity sensor, and initiate a treatment cycle during which the atomizing disinfectant generator dispenses atomized disinfectant fluid into the enclosed area.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: May 9, 2023
    Assignee: GCMG COMPANIES, LLC
    Inventors: Steve Grinstead, Frances Grinstead
  • Patent number: 11642428
    Abstract: A sterility-preserving robotic frontend-system, including a flexible trajectory-guide including at least one force- and/or torque-transmitting coupling-member, a baffle-member separating a sterile section from a non-sterile section, and a sterility-sleeve attached to the baffle-member; an actuator unit having a sensor unit that senses at least one of a) whether a trajectory-guide is placed with respect to the actuator unit in a manner that allows engaging-members to accurately engage an actuator interface, and b) whether the engaging-members have accurately engaged the actuator-interface; and a retainer-receptacle adapted to temporarily accommodate the trajectory guide, and to restrain flexibility of the trajectory-guide while it is accommodated. A packaging-container having an inner sterile volume containing the retainer-receptacle and the trajectory-guide and a method of setting up such a sterility-preserving robotic frontend-system.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 9, 2023
    Assignee: Brainlab AG
    Inventors: Wolfgang Steinle, Nils Frielinghaus, Stefan Hofberger
  • Patent number: 11642429
    Abstract: An oral sanitation system may include a case including: a support portion defining a lower end of the case; and a container portion extending from the support portion. The container portion may define a wall extending from the support portion to a top end of the container portion. The oral sanitation system may further include a closure including a lid formed with a peripherally-extending wall; a lower cavity defined by the wall of the container portion; an upper cavity defined by the peripherally-extending wall of the closure; and a light-guiding floor that is substantially transparent to UVC light, the light-guiding floor forming a bottom of the container portion that is surrounded by the wall.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: May 9, 2023
    Assignee: CUSTOM CLUB, INC.
    Inventors: Craig Weiss, Blair Feldman, Quinn Fitzgerald, Chloe Georgiades, Elliot Raderman